ClinicalTrials.gg
RecruitingNCT07680335BRIDGE-AD2Updated Jul 2, 2026

The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease

An interventional study of Plasma p-tau217 and neurofilament light chain results in Alzheimer Blood Biomarkers and Alzheimer's Disease (AD), sponsored by Alzheimercentrum Amsterdam. Recruiting at 8 sites in Netherlands. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Alzheimercentrum Amsterdam · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2025, registered Jun 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Alzheimer Disease with a site in Netherlands — 16 open to participants now, 27 under way, 9 of them phase 3. Alzheimer Disease · Netherlands.

Planned enrollment
32nd of 119
550 · median 241
Started
2025
with 10 others
No phase
14 of 133
3 open now
Primary completion
2026-12
later than 8 of 26 live
Registered
133rd of 133
by date

Among the 133 studies in Alzheimer Disease with a site in Netherlands, this one is the 32nd largest by planned enrollment of the 119 interventional ones that give a count, is one of 11 that started in 2025, is one of 14 with no phase, reaches primary completion later than 8 of the 26 other live ones, and was the 133rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

16 of the 133 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Alzheimer Disease with a site in Netherlands, or all of them as a file.
02

Study summary

Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary.

Blood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting.

This study aims to investigate clinical impact and diagnostic utility of blood-based biomarkers for AD in the diagnostic process of a memory clinic. The main objectives are to investigate change in diagnosis, diagnostic certainty and patient management, due to BBM results.

03

Conditions studied

  • Alzheimer Blood Biomarkers
  • Alzheimer's Disease (AD)

Browse trials for

Keywords

  • Randomised diagnostic trial
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presents in memory clinic with cognitive complaints.
  • The physician is concerned about underlying AD as etiology of the complaints.
  • Adequate fluency in Dutch to understand procedure.

Exclusion criteria

Exclusion Criteria:

  • Age under 55.
  • Previous biomarker-confirmed diagnosis of AD.
  • Alcohol or drug abuse to such an extent that treatment would be advisable.
  • Patient is incapacitated, and is not able to judge consequences of participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • No intervention
    Usual care path

    Blood-based biomarker results are not disclosed to the physician and/or patient, patient receives usual care and diagnostics

  • Experimental
    Blood-based biomarker results are made available to the physician

    In addition to usual care and diagnostics, blood-based biomarker results are sent to the physician who can disclose the results to the patient

    Diagnostic Test: Plasma p-tau217 and neurofilament light chain results

Interventions

  • Diagnostic testPlasma p-tau217 and neurofilament light chain results

    Results of the Quanterix Simoa ALZpath p-tau217 and Quanterix Simoa NfL assay.

06

What researchers measure

Primary outcomes

  1. Time from baseline to final diagnosis

    The time from baseline visit to final diagnosis will be reported in days.

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  2. Change in diagnosis

    Comparison between the diagnosis (syndrome diagnosis and etiology) before and after BBM testing. Change in diagnosis will be reported as yes/no.

    Time frame: From enrolment to when BBM test results have been disclosed to the physician, assessed up to 3 months

  3. Change in physician's confidence in diagnosis

    Comparison between physician's confidence in diagnosis before and after BBM testing within the intervention group. Physician's confidence will be measured on a 7-point Likert scale, with 1 being very uncertain and 7 being very certain.

    Time frame: From enrolment to when BBM test results have been disclosed to the physician, assessed up to 3 months

Secondary outcomes

  1. Difference between the intervention group and the control group in use and timing of ancillary tests

    Use of ancillary tests (yes/no), including neuropsychological evaluation, brain CT, brain MRI, CSF biomarker analysis, amyloid PET, FDG PET, DaT-SPECT, EEG/MEG, genetic testing, and speech therapy consultation. If performed, the timing in days from enrollment will be reported.

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  2. Concordance of BBM results with the presence of AD pathology according to CSF or amyloid PET

    Concordance will be defined as the percentage of BBM results (positive or negative) that is concordant with CSF or amyloid PET results (positive or negative).

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  3. Difference between the intervention group and the control group in patient management: follow-up duration

    Duration of patient follow-up (reported in days)

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  4. Difference between the intervention group and the control group in patient management: referral

    Referral to another specialist or center (yes/no)

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  5. Difference between the intervention group and the control group in patient management: prescription of medication

    Prescription of medication (yes / no; if yes which medication)

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

Other outcomes

  1. Usefulness of AD BBMs per case as perceived by the physician

    In the intervention group: Usefulness as perceived by the physician measured on a 5-point Likert scale with 1 being extremely unuseful and 5 being extremely useful. In the control group: Hypothetical usefulness (yes/no/maybe) as perceived by the physician in case the BBM results would have been received. In all cases: Desireability of the blood test being performed (yes/no) as perceived by the physician prior to receiving BBM results.

    Time frame: From enrolment to when BBM test results have been disclosed to the physician, assessed up to 3 months

  2. Patients' motivation for participation

    Participants will be asked to indicate their motivation for participation.

    Time frame: After the blood test is performed, assessed up to 3 months

  3. Patients' experience with receiving or not receiving BBM results

    Intervention group: Experience of receiving BBM results will be assessed by asking participants: * Whether not receiving the results would have been preferred (yes/no/I do not know) * Whether receiving the results had positive consequences (yes/no) * Whether receiving the results had negative consequences (yes/no) In the control group: experience of not receiving BBM results will be assessed by asking participants: \- Whether receiving the results would have been preferred (yes/no/I do not know)

    Time frame: After the blood test is performed, assessed up to 3 months

  4. Patient's understanding of the BBM results

    Participant's understanding will be assessed by asking participants whether the diagnosis changed after receiving BBM results. If yes, participants will be asked to indicate the initial diagnosis. Additionally, participants will be asked to explain, in their own words, what the BBM results meant.

    Time frame: After the blood test is performed, assessed up to 3 months

  5. Patients' satisfaction with the provision of information

    In case the results were disclosed to the patient: Satisfaction will be assessed by rating their agreement with 2 statements on a 5-point agree/disagree scale with 1 being strongly disagree and 5 being strongly agree.

    Time frame: After the blood test is performed, assessed up to 3 months

  6. Patients' satisfaction with the decision to participate

    In all cases: Satisfaction will be assessed by asking participants to rate their agreement with 4 statements on a 5-point decision regret scale with 1 being strongly disagree and 5 being strongly agree.

    Time frame: After the blood test is performed, assessed up to 3 months

  7. Cognitive performance measured by the MOCA

    Total scores of the Montreal Cognitive Assessment (MoCA) will be registered, if performed during clinical work-up. Scores range from 0 to 30.

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  8. Cognitive performance measured by the MMSE

    Total scores of the Mini-Mental State Examination (MMSE) will be registered, if performed during clinical work-up. Scores range from 0 to 30.

    Time frame: From enrolment to final diagnosis, assessed up to 100 months

  9. Survival

    Information on survival will be requested from Statistics Netherlands (Centraal Bureau voor de Statistiek; CBS), provided informed consent has been given for this (optional / separate question in ICF).

    Time frame: Up to 10 years after study completion

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — There are plans to share IPD through the ADDI platform, however a contract or data sharing agreement has not yet been established. Therefore it is not yet clear which specific IPD will be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 15 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jul 2, 2026
StartActual
Sep 17, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07680335
Lead sponsor
Alzheimercentrum Amsterdam
Collaborators
Davos Alzheimer's Collaborative, Quanterix Corporation (in kind)
Responsible party
Floor Duits (Dr., Alzheimercentrum Amsterdam) — Principal investigator
First posted
Jul 2, 2026
Start date
Sep 17, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Floor Duits, PhD
Contact
f.duits@amsterdamumc.nl
020 - 4440816

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion